David A. Siegel Sarepta Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 1,985,734 shares of SRPT stock, worth $33.9 Million. This represents 0.07% of its overall portfolio holdings.
Number of Shares
1,985,734
Previous 276,334
618.6%
Holding current value
$33.9 Million
Previous $17.6 Million
92.55%
% of portfolio
0.07%
Previous 0.04%
Shares
18 transactions
Others Institutions Holding SRPT
# of Institutions
463Shares Held
83.3MCall Options Held
5.6MPut Options Held
4.19M-
Black Rock Inc. New York, NY10.3MShares$176 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.16MShares$156 Million0.0% of portfolio
-
State Street Corp Boston, MA4.7MShares$80.1 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY4.48MShares$76.4 Million0.06% of portfolio
-
Wellington Management Group LLP Boston, MA2.53MShares$43.1 Million0.01% of portfolio
About Sarepta Therapeutics, Inc.
- Ticker SRPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,567,904
- Market Cap $1.49B
- Description
- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...